Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091084 | 0.84 | NPC1 (0.45) | KMT2ANPSR1MAPT | |
| SCHEMBL2094174 | 0.79 | GRIN2B (0.40) | KMT2AMAPT | |
| SCHEMBL2089950 | 0.78 | NPY5R (0.34) | KMT2AATMNPY5RSYKNPSR1 | |
| SCHEMBL2091939 | 0.76 | GRIN2B (0.45) | KMT2ANPSR1MAPT | |
| SCHEMBL2092086 | 0.72 | NPC1 (0.40) | KMT2ATDP1MAPT | |
| SCHEMBL2088778 | 0.72 | KDM4E (0.42) | KMT2AMAPT | |
| SCHEMBL2089520 | 0.71 | NPC1 (0.47) | KMT2A | |
| SCHEMBL2090183 | 0.70 | EPHX2 (0.39) | KMT2ATDP1MAPT | |
| SCHEMBL2091020 | 0.70 | EPHX2 (0.42) | — | |
| SCHEMBL7912442 | 0.68 | CYP1A2 (0.50) | KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | SCANIO MARC J C (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163914-B2 | Modulate neuronal nicotinic receptor activity; attention deficit disorder, Parkinson's, Tourette's, schizophrenia, cognitive deficits, dementia; acute pain, post-surgical pain, chronic pain, inflammatory pain; 2-[1-azatricyclo[3.3.1.13,7]dec-4-ylidene]-N-(4-methylphenyl)acetamide | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2069346-B1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | NAAA, AADAC, CD38 | KMT2A 228/4885ATM 3506/4885NPY5R 488/4885 |
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | NAAA, AADAC, CD38 | KMT2A 228/4885ATM 3506/4885NPY5R 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.